Breast cancer prevention—clinical trials strategies involving aromatase inhibitors

This publication has 10 references indexed in Scilit:

• First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial
  The Lancet, 2002
• American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition
  Journal of Clinical Oncology, 2002
• Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
  JAMA, 2002
• SERMs: current status and future trends
  Critical Reviews in Oncology/Hematology, 2002
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
  The Lancet, 2002
• Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective Studies
  JNCI Journal of the National Cancer Institute, 2002
• Serum Estradiol Level and Risk of Breast Cancer During Treatment With Raloxifene
  JAMA, 2002
• Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
  Endocrine-Related Cancer, 2001
• Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development
  Human Reproduction Update, 2001
• The importance of local synthesis of estrogen within the breast
  Steroids, 1987